Indolent B-Cell Malignancies: Immune Recognition and Antiself

References

• Maloney, D.G., Grillo-Lopez, A.J., Bodkin, D.J., White, C.A., Liles, T.M., Royston, I., et al. (1997) "IDEC-C2B8: results of a phase I multiple dose trial in patients with relapsed non-Hodgkin's lymphoma", Blood, 90, 3266— 3274.
   Google Scholar
• McLaughlin, P., Grillo-Lopez, A.J., Link, BK., Levy, R., Czucz-man, M.S., Williams, ME., et al. (1998) "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lympho-ma: half of patients respond to a four-dose treatment program", Journal of Clinical Oncology, 16, 2825–2833.
   PubMed Web of Science ®Google Scholar
• Davis, TA., Grillo-Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, BK., et al. (2000) "Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment", Journal of Clinical Oncology, 18, 3135–3143.
   PubMed Web of Science ®Google Scholar
• Czuczman, M.S., Grillo-Lopez, A.J., White, CA., Saleh, M., Gordon, L., LoBuglio, A.F., et al. (1999) "Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy", Journal of Clinical Oncology, 17, 268–276.
   PubMed Web of Science ®Google Scholar
• Kaminski, M.S., Estes, J., Zasasry, KR., Francis, I.R., Ross, C.W., Tuck, M., et al. (2000) "Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood, 96, 1259 — 1266.
   Google Scholar
• Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, A.Z., Knox, Si., Radford, J.A., et al. (2000) "Multicenter phase II study of iodine-131 tositumomab for chemotherapy relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas", Journal of Clinical Oncology, 18, 1316— 1323.
   PubMed Web of Science ®Google Scholar
• Multani, P.S., O'Day, S., Nadler, L.M. and Grossbard, M.L. (1998) "Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma", Clinical Cancer Research, 4, 2599 — 2604.
   Google Scholar
• Grossbard, ML., Niedzwiecki, D., Nadler, L.M., Fruchtman, S.M., Schuster, M., Pecora, A., et al. (1998) "Anti-B4 blocked ricin (anti-B4bR) adjuvant therapy post autologous bone marrow transplant: a Phase III Intergroup study", Proceedings of the American Society for Clinical Oncology, 17, 3a [abstract 8].
   Google Scholar
• Maloney, D.G., Grillo-Lopez, A.J., White, CA., Bodkin, D., Schilder, R.J., Neidhart, JA., et al. (1997) "IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed lower-grade non-Hodgkin's lymphoma", Blood, 90, 2188 — 2198.
   Google Scholar
• Hainsworth, JD., Burris, H.A. III, Morrissey, L.H., Litchy, S., Scullin, D.C. Jr, Bearden, J.D. III, et al. (2001) "Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma", Proceedings of the American Society for Clinical Oncology, 20, 294a [abstract 1175].
   Google Scholar
• Gutheil, J.C., Funicane, D., Rodriguez, R., Saleh, F., Stahler, S. and Royston, I. (2000) "Phase II study of rituximab in patients with previously untreated low-grade or follicular non-Hodgkin's lym-phoma", Proceedings of the American Society for Clinical Oncology, 19, 22a [abstract 79].
   Google Scholar
• Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., et al. (2001) "Rituximab as single first-line therapy for patients with follicular lymphomas with a low tumor burden: clinical and molecular evaluation", Blood, 97, 101–106.
   Google Scholar
• Czuczman, M.S., Grillo-Lopez, A.J., White, C.A., Saleh, M., Gordon, L.I., Lo Buglio, A.F., et al. (2001) "Progression-free survival after 6 years (median) follow-up of the first clinical trial of rituximab/CHOP chemoimmunotherapy", Blood, 98, 601a [abstract 2519].
   Google Scholar
• Czuczman, M.S., Fallon, A., Mohr, A., Stewart, C., Klippenstein, D., Lond, P., et al. (2001) "Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report", Blood, 98, 601a [abstract 2518].
   Google Scholar
• Zinzani, P.L., on behalf of an Italian Cooperative Study Group on Lymphoma. (2001) "A randomised trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma", Blood, 98, 842a [abstract 35001.
   Google Scholar
• Hiddemann, W., Forstpointer, R., Fiedler, F., Gramatzki, M., Dorkin, B., Illiger, H.-J., et al. for the GLSG (2001) "The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantle cell lymphomas (MCL): results of a prospective randomized compar-ison of the German Low Grade Study Group (GLSG)", Blood, 98, 844a [abstract 3507].
   Google Scholar
• Kaminski, M.S., Zelenetz, A.D., Press, OM., Saleh, M., Leonard, J., Fehrenbacher, L., et al. (2001) "Pivotal study of Bexxar (iodine I 131 tositumomab) for chemotherapy-refractory low-grade or transformed B-cell non-Hodgkin's lymphomas", Journal of Clinical Oncology, 19, 3918–3928.
   PubMed Web of Science ®Google Scholar
• Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., et al. (2002) "Randomized controlled trial of yttrium-90—labeled ibritumomab tiuxetan radioimmu-notherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma", Journal of Clinical Oncology, 20, 2453— 2463.
   PubMed Web of Science ®Google Scholar
• Liu, S.Y., Eary, J.F., Petersdorf, S.H., Martin, P.J., Maloney, D.G., Appelbaum, F.R., et al. (1998) "Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem cell rescue", Journal of Clinical Oncology, 16, 3270–3279.
   PubMed Web of Science ®Google Scholar
• Press, OW., Eary, J.F., Gooley, T., Gopal, AK., Liu, S., Rajendran, J.G., et al. (2000) "A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and auto-logous stem cell transplantation for relapsed B-cell lymphomas", Blood, 96, 2934–2942.
   PubMed Web of Science ®Google Scholar
• Press, OM., Unger, J.M., Braziel, R.M., Maloney, D.G., Miller, T.P., LeBlanc, M., et al. (2003) "A Phase II trial of CHOP chemotherapy followed by tositumomab/iodine 1131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Southwest Oncology Group protocol S9911", Blood, May 8 [Epub ahead of print].
   Google Scholar
• Ratanatharathorn, V., Uberti, J., Karanes, C., Abella, E., Lum, L.G., Momin, F., et al. (1994) "Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma", Blood, 84, 1050— 1055.
   Google Scholar
• Jones, R.J., Ambinder, R.F., Piantadosi, S. and Santos, G.W. (1991) "Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation", Blood, 3, 649 — 653.
   Google Scholar
• Vandenberghe, P. and Boogaerts, M.A. (1995) "Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfu-sions", Annals of Hematology, 71, 209–217.
   Google Scholar
• Lin, H., Bolling, S.F., Linsley, P.S., Wei, R.Q., Gordon, D., Thompson, C.B., et al. (1993) "Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4-Ig plus donor-specific transfusion", Journal of Experi-mental Medicine, 178, 1801 — 1806.
   Web of Science ®Google Scholar
• Lenschow, D.J., Zeng, Y., Thistlethwaite, J.R., Montag, A., Brady, W., Gibson, M.G., et al. (1992) "Long-term survival of xenogeneic pancreatic islets grafts induced by CTLA4-Ig", Science, 257, 789 — 792.
   PubMed Web of Science ®Google Scholar
• Kirk, A.D., Harlan, D.M., Armstrong, N.N., Davis, T.A., Dong, Y., Gray, G.S., et al. (1997) "CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates", Proceedings of the National Academy of Sciences of the United States of America, 94, 8789 —8794.
   PubMed Web of Science ®Google Scholar
• Guinan, E.C., Boussiotis, V.A., Neuberg, D., Brennan, L.L., Hirano, N., Nadler, L.M., et al. (1999) "Transplantation of anergic histoincompatible bone marrow allografts", New England Journal of Medicine, 340, 1704 — 1714.
   Web of Science ®Google Scholar
• Schultze, J.L., Cardoso, A.A., Freeman, G.J., Seamon, M.J., Daley, J., Pinkus, G.S., et al. (1995) "Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity", Proceedings of the National Academy of Sciences of the United States of America, 92, 8200— 8204.
   Google Scholar
• Buhmann, R., Nolte, A., Westhaus, D., Emmerich, B. and Hallek, M. (1999) "CD40-activated B cell chronic lymphocytic leukaemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells", Blood, 93, 1992–2002.
   Google Scholar
• Schultze, J.L., Michalak, S., Seamon, M.J., Dranoff, G., Jung, K., Daley, J., et al. (1997) "CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immu-notherapy", Journal of Clinical Investigation, 100, 2757–2765.
   Google Scholar
• Ranheim, E.A. and Kipps, T.J. (1993) "Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal", Journal of Experimental Medicine, 177, 925–935.
   PubMed Web of Science ®Google Scholar
• Yellin, M.J., Sinning, J., Covey, L.R., Sherman, W., Lee, J.J., Glickman-Nir, E., et al. (1994) "T lymphocyte T cell-B cell activating molecule/CD4O-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity", Journal of Immunology, 153, 666 — 674.
   PubMed Web of Science ®Google Scholar
• Van den Hove, L.E., Van Gool, SM., Vandenberghe, P., Bakkus, M., Thielemans, K., Boogaerts, M.A., et al. (1997) "CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules", Leukemia, 11, 572–580.
   PubMed Web of Science ®Google Scholar
• Dorfman, D.M., Schultze, J.L., Shahsafaei, A., Michalak, S., Gribben, J.G., Freeman, G.J., et al. (1997) "In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation", Blood, 90, 4297–4306.
   PubMed Web of Science ®Google Scholar
• Maliszewski, C. (2001) "Dendritic cells I models of tumor immunity. Role of F1t3 ligand", Pathologie-Biologie, 49, 481 —483.
   PubMedGoogle Scholar
• Timmerman, J.M. and Levy, R. (2001) "The history of the development of vaccines for the treatment of lymphoma", Clinical Lymphoma, 1, 129–139.
   Google Scholar
• Stevenson, G.T. (1977) "Idiotypic determinants on the surface of immunoglobulin of neoplastic lymphocytes: a therapeutic target", Federation Proceedings, 36, 2268 — 2271.
   PubMed Web of Science ®Google Scholar
• Wen, Y.J. and Lim, S.H. (1997) "T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma", European Jourmal of Immunol-ogy, 27, 1043–1047.
   Google Scholar
• George, A.J.T. and Stevenson, F.K. (1989) "Prospects for the treatment of B cell tumors using idiotypic vaccination", Interna-tional Reviews of Immunology, 4, 271 — 310.
   Google Scholar
• Kwak, LW., Campbell, M.J., Czerwinski, D.K., Hart, S., Miller, R.A. and Levy, R. (1992) "Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors", New England Journal of Medicine, 327, 1209 — 1215.
   Google Scholar
• Hsu, F.J., Caspar, C.B., Czerwinski, D., Kwak, LW., Liles, TM., Syrengelas, A., et al. (1997) "Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma — long-term results of a clinical trial", Blood, 89, 3129 — 3135.
   Google Scholar
• Bendandi, M., Gocke, CD., Kobrin, CD., Benko, F.A., Sternas, L.A., Pennington, R., et al. (1999) "Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma", Nature Medicine, 5, 1171— 1177.
   Google Scholar
• Trojan, A., Schultze, J.L., Witzens, M., Vonderheide, R.H., Ladetto, M., Donovan, J.W., et al. (2000) "Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B cell malignancies", Nature Medicine, 6, 667 —672.
   Google Scholar
• Wen, Y.J., Barlogiem, B. and Yi, Q. (2001) "Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells", Blood, 97, 1750 — 1755.
   Google Scholar
• Campbell, M.J., Esserman, L., Byars, N.E., Allison, AC. and Levy, R. (1990) "Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity", Journal of Immunology, 145, 1029— 1036.
   Google Scholar
• Osterroth, F., Garbe, A., Fisch, P. and Veelken, H. (2000) "Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells", Blood, 95, 1342–1349.
   Google Scholar
• Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W.M., et al. (1994) "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes", Journal of Immunology, 153, 5586–5592.
   Google Scholar
• van der Burg, S.H., Visseren, Mi., Brandt, R.M., Kast, W.M. and Melief, C.J. (1996) "Immunogenicity of peptides bound to MHC class I molecules depends of the MHC peptide complex stability", Journal of Immunology, 156, 3308–3314.
   Google Scholar
• Savage, PA., Boniface, J.J. and David, M.M. (1999) "A kinetic basis for T cell receptor repertoire selection during an immune response", Immunity, 10, 485 —492.
   Google Scholar
• Rammensee, H., Bachmann, J., Emmerich, NP., Bachor, O.A. and Stevanovic, S. (1999) "SYFPEITHI: database for MHC ligands and peptide motifs", Immunogenetics, 50, 213–219.
   Google Scholar
• Muller, D., Pederson, K., Murray, R. and Frelinger, J.A. (1991) "A single amino acid substitution in and MHC class I molecule allows heteroclitic recognition by lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes", Journal of Immunology, 147, 1392— 1397.
   Google Scholar
• Hang, S., Witzens, M., Krackhardt, A.M., Trojan, A., Barrett, P., Broderick, R., et al. (2001) "Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues", Blood, 98, 2999 — 3005.
   PubMedGoogle Scholar
• Krackhardt, A.M., Witzens, M., Hang, S., Hodi, F.S., Zauls, A.J., Chessia, M., et al. (2002) "Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX", Blood, 100, 2123–2131.
   Google Scholar
• Murray, G.I., Melvin, W.T., Greenlee, W.F. and Burke, M.D. (2001) "Regulation, function, and tissue-specific expression of cytochrome p450 CYPIBI", Annual Review of Pharmacology and Toxicology, 41, 297 — 316.
   PubMed Web of Science ®Google Scholar
• Murray, G.I., Taylor, MC., McFadyen, MC., McKay, J.A., Greenlee, W.F., Burke, M.D., et al. (1997) "Tumor-specific expression of cytochrome P450 CYPIBI", Cancer Research, 57, 3026–3031.
   PubMed Web of Science ®Google Scholar